NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ternary Therapeutics

Ternary Therapeutics

Private
LondonHealthcare & Life Scienceshttps://www.ternarytx.co.uk/

Last Round

Seed

Mar 16, 2026

Total Funding Raised

$4.6M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Ternary Therapeutics is a biotechnology company that develops an AI-driven platform for the rational design of molecular glue therapeutics targeting immunological disorders.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, ML Platforms

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

molecular gluedrug discoveryAI drug discoverytech-biorational drug designprotein-protein interactionsundruggable targetsmolecular dynamicsvirtual screeningin silico drug designcomputational biologyprotein structure predictionbiotech platformsmall molecule therapeuticsAI-driven R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ternary Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Ternary Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Ternary Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMar 16, 2026
SeedFeb 27, 2025

Key People

Founding team and executive leadership

Andrew Potterton

Chief Technology Officer and Co-Founder

Founding Team

Chris Tame

Founder and CEO

Founding Team

Ternary Therapeutics Investors

Notable investors and investment history

Ternary Therapeutics investors
InvestorRounds
Pace VenturesSeed
DaphniSeed
UK Innovation & Science Seed FundSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2026

    Grew 25% QoQ from 12 to 15 employees.

Ternary Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ternary Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ternary Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range15
Year Founded2024
Last FundingMar 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.